.

Pharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Predict branded drug patent expiration
  • Set up watchlists for daily email updates

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

Osimertinib mesylate - Generic Drug Details

« Back to Dashboard

What are the generic drug sources, and freedom to operate, for osimertinib mesylate?

Osimertinib mesylate is the generic ingredient in one branded drug marketed by Astrazeneca Pharms and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Osimertinib mesylate has sixty-five patent family members in thirty-one countries.

One supplier is listed for this compound.

Summary for Generic Name: osimertinib mesylate

Tradenames:1
Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list13
Clinical Trials: see list185
Patent Applications: see list3
Drug Prices:see low prices
DailyMed Link:osimertinib mesylate at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca Pharms
TAGRISSO
osimertinib mesylate
TABLET;ORAL208065-002Nov 13, 2015RXYesYes► Subscribe► Subscribe
Astrazeneca Pharms
TAGRISSO
osimertinib mesylate
TABLET;ORAL208065-001Nov 13, 2015RXYesNo► Subscribe► Subscribe
Astrazeneca Pharms
TAGRISSO
osimertinib mesylate
TABLET;ORAL208065-001Nov 13, 2015RXYesNo► Subscribe► Subscribe
Astrazeneca Pharms
TAGRISSO
osimertinib mesylate
TABLET;ORAL208065-002Nov 13, 2015RXYesYes► Subscribe► Subscribe
Astrazeneca Pharms
TAGRISSO
osimertinib mesylate
TABLET;ORAL208065-002Nov 13, 2015RXYesYes8,946,235► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: osimertinib mesylate

Country Document Number Estimated Expiration
Eurasian Patent Organization201690328► Subscribe
Denmark2736895► Subscribe
Ukraine108954► Subscribe
Japan2014094930► Subscribe
Eurasian Patent Organization024421► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc